Creative Planning Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Creative Planning increased its holdings in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 79.6% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 52,855 shares of the biopharmaceutical company’s stock after purchasing an additional 23,433 shares during the period. Creative Planning’s holdings in Amicus Therapeutics were worth $564,000 as of its most recent SEC filing.

Several other institutional investors also recently bought and sold shares of FOLD. Assenagon Asset Management S.A. acquired a new position in Amicus Therapeutics during the 2nd quarter valued at approximately $8,386,000. M&G Plc raised its stake in Amicus Therapeutics by 12.4% in the 2nd quarter. M&G Plc now owns 748,451 shares of the biopharmaceutical company’s stock worth $7,485,000 after acquiring an additional 82,728 shares during the last quarter. Edgestream Partners L.P. lifted its position in Amicus Therapeutics by 1,290.4% during the 1st quarter. Edgestream Partners L.P. now owns 270,164 shares of the biopharmaceutical company’s stock worth $3,183,000 after acquiring an additional 250,734 shares during the period. CANADA LIFE ASSURANCE Co grew its stake in Amicus Therapeutics by 7.8% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 100,538 shares of the biopharmaceutical company’s stock valued at $1,183,000 after purchasing an additional 7,304 shares during the last quarter. Finally, Fiera Capital Corp increased its holdings in shares of Amicus Therapeutics by 1.1% in the second quarter. Fiera Capital Corp now owns 5,280,442 shares of the biopharmaceutical company’s stock valued at $52,382,000 after purchasing an additional 58,113 shares during the period.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on FOLD. StockNews.com lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, October 31st. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Friday, August 9th. Bank of America lifted their price objective on Amicus Therapeutics from $13.00 to $15.00 and gave the company a “buy” rating in a research note on Thursday, October 17th. JPMorgan Chase & Co. dropped their target price on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating on the stock in a report on Friday, August 16th. Finally, Jefferies Financial Group began coverage on Amicus Therapeutics in a report on Friday, September 6th. They issued a “buy” rating and a $18.00 price target for the company. Two research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $17.13.

Insider Activity at Amicus Therapeutics

In other news, CEO Bradley L. Campbell sold 7,500 shares of Amicus Therapeutics stock in a transaction that occurred on Tuesday, October 1st. The shares were sold at an average price of $10.60, for a total transaction of $79,500.00. Following the completion of the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $9,398,532.40. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders sold a total of 22,500 shares of company stock worth $253,275 over the last 90 days. Company insiders own 2.20% of the company’s stock.

Amicus Therapeutics Trading Down 1.2 %

FOLD opened at $11.33 on Tuesday. The business’s 50-day simple moving average is $11.15 and its 200-day simple moving average is $10.59. The company has a market cap of $3.36 billion, a P/E ratio of -29.05 and a beta of 0.68. Amicus Therapeutics, Inc. has a one year low of $9.02 and a one year high of $14.57. The company has a debt-to-equity ratio of 2.93, a quick ratio of 2.26 and a current ratio of 2.75.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.05). The firm had revenue of $126.67 million for the quarter, compared to analyst estimates of $121.21 million. Amicus Therapeutics had a negative return on equity of 41.47% and a negative net margin of 26.23%. The business’s revenue was up 34.0% on a year-over-year basis. During the same quarter last year, the company posted ($0.15) earnings per share. As a group, equities research analysts expect that Amicus Therapeutics, Inc. will post -0.06 EPS for the current fiscal year.

About Amicus Therapeutics

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.